Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Self-Injectable Drug Coverage Rule Expected By Spring

Executive Summary

The Centers for Medicare & Medicaid Services expects to issue a memorandum expanding Medicare coverage for self-injectable pharmaceuticals by spring

You may also be interested in...



CMS Medicare Self-Injectable Guidelines Maintain Split Within Drug Classes

The Centers for Medicare & Medicaid Services' self-injectables guidelines would still divide Medicare coverage within a therapeutic drug class based on route of administration

CMS Medicare Self-Injectable Guidelines Maintain Split Within Drug Classes

The Centers for Medicare & Medicaid Services' self-injectables guidelines would still divide Medicare coverage within a therapeutic drug class based on route of administration

Enbrel Shortage Strategies: Clinical Trials Will Provide “Bolus” Of Patients

Immunex' ongoing Enbrel clinical trials will help provide a "bolus" of patients for the rheumatoid arthritis agent once the company expands its commercial capacity for the biologic

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel